Key result
Edoxaban is linked to ~33% lower stroke or systemic embolism risk vs VKAs in AF.
Why the study?
Observational studies comparing the effectiveness and safety of edoxaban with other oral anticoagulants in patients with AF have yielded disputed results.
Does edoxaban reduce the risk of stroke, systemic embolism, and bleeding compared with other oral anticoagulants in patients with atrial fibrillation?
Population
Patients with AF across 17 observational studies
Comparison
Edoxaban vs other oral anticoagulants
Design
Systematic review and meta-analysis of observational studies
Authors
Loading...
Supports preferring edoxaban over vitamin K antagonists; extends comparative data among oral anticoagulants.
Meta-Analysis
Does edoxaban reduce the risk of stroke, systemic embolism, and bleeding compared with other oral anticoagulants in patients with atrial fibrillation?
Relative Risk: 0.67 (95% CI 0.61–0.74)
Edoxaban may offer superior effectiveness and/or safety outcomes compared to vitamin K antagonists, dabigatran, rivaroxaban, and apixaban for stroke prevention in patients with atrial fibrillation.
Zhang et al. (2023) conducted a meta-analysis in Atrial fibrillation. Edoxaban vs. Other oral anticoagulants (vitamin K antagonists, dabigatran, rivaroxaban, apixaban) was evaluated on Stroke or systemic embolism (RR 0.67, 95% CI 0.61-0.74). Edoxaban was associated with a lower risk of stroke or systemic embolism compared with vitamin K antagonists (RR 0.67; 95% CI 0.61-0.74) in patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: